Fig. 6: IL-16 enhances the sensitivity of ICB therapy. | Nature Communications

Fig. 6: IL-16 enhances the sensitivity of ICB therapy.

From: Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice

Fig. 6

Mice inoculated with E0771 cells (a, n = 5 for PBS groups, n = 7 for IL-16 groups) or LLC cells (b, n = 4/group) were i.p. administered with IL-16 (0.8 μg), αPD-L1 (150 μg), or in combination, tumor growth was measured. c The expressions of indicated genes in E0771 tumors were evaluated by QPCR. d E0771 mice were administered with a CXCR3 inhibitor (NBI-74330) and co-treated with IL-16 + αPD-L1 therapy (n = 4/group); tumor growth was monitored. e The cell-specific expression of CXCL9 and CXCL10 in tumor tissues from breast cancer patients (n = 6) was analyzed using scRNA-seq. f E0771 mice were administered with clodronate liposomes to deplete TAMs (MφΔ) (n = 5 for Ctrl groups, n = 6 for MφΔ groups), followed by IL-16 + αPD-L1 treatment, tumor growth was measured. ANOVA (a–d, f) was used. Data are presented as mean ± SD.

Back to article page